Today, there are no safe, effective and fast-acting treatments that provide benefit to patients through modulation of circadian rhythms.
To address this, Circadian Therapeutics has identified drug candidates and is looking to study their effects on circadian rhythms in clinical trials.
Circadian's intellectual property draws on the input of the Nuffield Department of Clinical Neurosciences, the Department of Pharmacology, and the Institute of Biomedical Engineering, and builds on research supported by the Wellcome Trust.